Results 101 to 110 of about 447,359 (150)

P152 | IMPACT OF POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS UNDERGOING ALLOGENEIC TRANSPLANTATION FROM A HAPLOIDENTICAL DONOR, MUD OR MMUD. SINGLE-CENTER EXPERIENCE AT THE TRANSPLANT AND CELLULAR THERAPY CENTER, GOM, REGGIO CALABRIA

open access: yesHaematologica
Background The introduction of post-transplant cyclophosphamide (PTCy) has improved outcomes in haploidentical hematopoietic stem cell transplantation (HSCT), reducing non-relapse mortality (NRM) and preventing graft-versus-host disease (GVHD).
G. Lazzaro   +13 more
doaj  

"Technology" in the context of images and meanings of the fundamental "education" category

open access: yes, 2013
В статье определяется место "технологии" в современном контексте образования, аргументируется недопустимость абсолютизации технологии.The article defines the place of "technology" in the current context of education, argues the ...
Белозерцев, Евгений Петрович
core  

Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study. [PDF]

open access: yesBreast Cancer Res Treat
Tolosa P   +25 more
europepmc   +1 more source

[Byron "Bam" Morris 1]

open access: yes, 2016
Undated photograph of football player Byron "Bam" ...
Granberry, Walter.
core  

Virtual cell: Current perspectives and future prospects. [PDF]

open access: yesJ Int Med Res
Li J   +5 more
europepmc   +1 more source

Predicting adolescent depression: an interpretable machine learning model. [PDF]

open access: yesBMC Med Inform Decis Mak
Chen X   +11 more
europepmc   +1 more source

P225 | IMPROVED OUTCOME WITH AVAPRITINIB VS MIDOSTAURIN IN SYSTEMIC MASYOCYTOSIS: A SINGLE-CENTER EXPERIENCE

open access: yesHaematologica
BACKGROUND: Adverse systemic mastocytosis (AdvSM) includes the most aggressive SM subtypes; cKITD816V is recognized as a driver mutation in ~95% of cases. Therefore, Tyrosine Kinase Inhibitors (TKIs) represent the standard of care. Avapritinib is a new,
M. Fazio   +6 more
doaj  

Home - About - Disclaimer - Privacy